Completed Clinical Trial Further Indicates Cell-in-a-Box® Encapsulation Technology Has the Potential to Treat a Wide Array o...
March 15 2012 - 10:43AM
Business Wire
Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider
of cell and gene therapy solutions through its ongoing acquisition
of the assets of SG Austria, realizes the important role for
Cell-in-a-Box® technology, and what it offers the medical
community, and aims today to discuss the potential it will serve as
a treatment option for a variety of solid tumors.
As discussed previously, the Cell-in-a-Box® technology involves
the encapsulating, or encasing of live cells in a specially created
cotton-based capsule. The cell-type chosen, in the case of cancer
treatment it is a cytochrome P450 expressing cell, is chosen for
the disease and then is ultimately placed beside or within the
target tumor while the cells remain inside the capsule. For cancer,
once a patient receives the drug to be converted, the encapsulated
cells transform this into an active chemotherapeutic. As a result,
a high concentration of the drug is provided locally to the
tumor.
Although the original human clinical trials were limited to
pancreatic cancer tumors, later work showed the Cell-in-a-Box®
encapsulation technology has great potential for use in other solid
tumors. The work also pointed toward encapsulated cells expressing
more than one drug-activating enzyme as being of potential value in
treating other cancers, indicating the possibility of combination
drug therapies targeted by one or more encapsulated cell product(s)
being placed in or near the tumor to cause a high level of
chemotherapy at the site it’s intended for.
Most chemotherapy drugs affect both normal and cancerous tissue,
which is why they are so toxic to naturally fast-growing cells in
the body, such as hair follicles and intestinal cells. By using
encapsulated cytochrome P450 expressing cells to convert the drug
locally and then placing them close to or in a tumor, much less
active drug is available to cause harm to healthy normal cells and
instead its localized high concentration remains in the tumor
region, irrespective of solid tumor type being treated, and thereby
can increase elimination of the tumor cells.
Dr. Robert Ryan, Chief Executive Officer of Nuvilex, added, “The
work that continues to be advanced by SG Austria expands the
possible use of the Cell-in-a-Box® technology beyond pancreatic
cancer. When combined with the potential downstream affect on micro
metastases through use of encapsulated cells, we can realistically
imagine being able to treat cancers across a broad spectrum. Our
goal is to minimize normal cell and tissue damage, reduce the
life-threatening side effects, and yet bring about elimination of a
person’s cancer. Over the past year and through today, we have
continued to research new ways to improve on the quality and
quantity of the products we will be driving forward, including the
pancreatic cancer treatment, all of which are designed to increase
the quality of our lives through effective use of live cell
encapsulation.”
About Nuvilex
Nuvilex, Inc. (OTCQB:NVLX) is an emerging international
biotechnology provider of clinically useful therapeutic live
encapsulated cells and services for encapsulating live cells for
the research and medical communities. Through our effort, all
aspects of our corporate activities alone, and especially in
concert with SG Austria, are rapidly moving toward completion,
including closing our agreement. One of our planned offerings will
include cancer treatments using the company’s industry-leading
live-cell encapsulation technology.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
involving risks and uncertainties. Results, events and performances
could vary from those contemplated. These statements involve risks
and uncertainties which may cause actual results, expressed or
implied, to differ from predicted outcomes. Risks and uncertainties
include product demand, market competition, and Nuvilex’s ability
to meet current or future plans. Investors should study and
understand all risks before making an investment decision. Readers
are recommended not to place undue reliance on forward-looking
statements or information. Nuvilex is not obliged to publicly
release revisions to any forward-looking statement, to reflect
events or circumstances afterward, or to disclose unanticipated
occurrences, except as required under applicable laws.